Showing 1631-1640 of 2793 results for "".
- SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lineshttps://modernaesthetics.com/news/scale-2026-ipsen-reports-phase-2-corabotase-data-in-glabellar-lines/2487141/Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee. The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng ac
- Direct Brow Lift Shows Durable Results and High Satisfaction in Prospective Studyhttps://modernaesthetics.com/news/direct-brow-lift-shows-durable-results-and-high-satisfaction-in-prospective-study/2487140/A prospective study published online ahead of print in Aesthetic Plastic Surgery evaluated the long-term efficacy, scar-related outcomes, and patient satisfaction associated with the direct brow lift using the Castanares tec
- Aesthetic Meet 2026: The Aesthetic Society Names Dr. Jamil Ahmad Presidenthttps://modernaesthetics.com/news/aesthetic-meet-2026-the-aesthetic-society-names-dr-jamil-ahmad-president/2487120/The Aesthetic Society has named Jamil Ahmad, MD, as its President, and The Aesthetic Foundation has named David A. Sieber, MD, as President, during The Aesthetic MEET 2026 in Boston. Dr. Ahmad assumes leadership as The Society reports membership growth of more than 30%, with new members fr
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://modernaesthetics.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- SCALE 2026: Ipsen to Present Phase II Corabotase Datahttps://modernaesthetics.com/news/scale-2026-ipsen-to-present-phase-ii-corabotase-data/2487087/Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule. Corabotase is described by Ipsen as a custom-designed recombinant neuroi
- Review Examines Dermatologic Effects of Rapid Weight Losshttps://modernaesthetics.com/news/review-examines-dermatologic-effects-of-rapid-weight-loss/2486984/Rapid weight loss associated with bariatric surgery, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and intensive lifestyle interventions may contribute to dermatologic and structural changes that extend beyond reduced body size, according to a narrative rev
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://modernaesthetics.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Dermalogica Enters Device Market With FDA-Cleared Microneedling Systemhttps://modernaesthetics.com/news/dermalogica-enters-device-market-with-fda-cleared-microneedling-system/2486887/Dermalogica has announced the launch of its PRO Pen Microneedling System following US Food and Drug Administration (FDA) 510(k) clearance, marking the company’s first entry into the medical device category. The device is indicated for the treatment of facial acne scars in adults aged 22 years and
- 12-Month Data Support Durability of Click-Crosslinked HA for Nasolabial Foldhttps://modernaesthetics.com/news/12-month-data-support-durability-of-click-crosslinked-ha-for-nasolabial-fold/2486822/A novel long-chain hyaluronic acid (HA) filler utilizing click-chemistry crosslinking demonstrated sustained efficacy and a favorable safety profile for nasolabial fold (NLF) correction in 2 prospective studies published in the Journal of Cosmetic Dermatology. Traditional HA fille
- Revance Highlights RHA Dynamic Volume Mid-Face FDA Approval at Virtual Desk Sidehttps://modernaesthetics.com/news/revance-highlights-rha-dynamic-volume-mid-face-fda-approval-at-virtual-desk-side/2486819/Revance Aesthetics hosted a virtual desk side with Lesley Clark-Loeser, MD, to discuss the recent US Food and Drug Administration (FDA) approval of RHA Dynamic Volume for cheek augmentation and correction of age-related mid-face contour deficiencies in adults aged 22 years and older. The a